Resmetirom
Brand names: Rezdiffra · Active ingredient: Resmetirom
In short: REZDIFFRA® is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibros
What is Resmetirom used for?
REZDIFFRA® is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
This indication is approved under accelerated approval based on improvement of MASH and fibrosis . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Limitations of Use
Avoid use of REZDIFFRA in patients with decompensated cirrhosis .
Resmetirom dosage
The recommended dosage of REZDIFFRA is based on actual body weight. For patients weighing:
<100 kg, the recommended dosage is 80 mg orally once daily.
≥100 kg, the recommended dosage is 100 mg orally once daily.
Administer REZDIFFRA with or without food .
Swallow REZDIFFRA tablets whole; do not split, crush, or chew tablets.
Advise patients that if a dose is missed, do not take the missed dose and resume with the next scheduled dose.
Concomitant use of REZDIFFRA with strong CYP2C8 inhibitors (e.g., gemfibrozil) is not recommended .
If REZDIFFRA is used concomitantly with a moderate CYP2C8 inhibitor (e.g., clopidogrel) , reduce the dosage of REZDIFFRA:
<100 kg, reduce the dosage of REZDIFFRA to 60 mg once daily.
≥100 kg, reduce the dosage of REZDIFFRA to 80 mg once daily.
How to take Resmetirom — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Administration Instructions
Instruct patients to swallow REZDIFFRA tablets whole and not split, crush, or chew tablets .
Hepatotoxicity
Inform patients of the risk of hepatotoxicity. Instruct patients to immediately report any signs or symptoms of severe liver injury (e.g., fatigue, nausea, vomiting, right upper quadrant pain or tenderness, jaundice, fever, rash) to their healthcare provider .
Gallbladder-Related Adverse Reactions
Inform patients of the potential risk for cholelithiasis, cholecystitis, and obstructive pancreatitis (gallstones) during treatment with REZDIFFRA. Instruct patients to contact their healthcare provider if they develop signs or symptoms of these conditions .
Drug Interaction with Statins
Inform patients that concomitant use of REZDIFFRA with some statins may increase the risk of statin-related adverse reactions (e.g., elevation of liver tests, myopathy, rhabdomyolysis) .
Pregnancy
Inform patients that there is a pregnancy safety study that monitors pregnancy outcomes in women exposed to REZDIFFRA during pregnancy. …
Warnings & precautions
Do not take this medicine if: None.
Hepatotoxicity has been observed with use of REZDIFFRA. One patient had normal alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TB) levels at baseline, who received REZDIFFRA 80 mg daily, developed substantial elevations of liver biochemistries that resolved when treatment was interrupted. After reinitiating REZDIFFRA, the patient had elevations of ALT, AST, and TB. Peak values observed were 58 x upper limit of normal (ULN) for ALT, 66 x ULN for AST, 15 x ULN for TB, with no elevation of alkaline phosphatase (ALP). Elevations in liver enzymes were accompanied by elevations in immunoglobulin G levels, suggesting drug-induced autoimmune-like hepatitis (DI-ALH). The liver tests returned to baseline following hospitalization and discontinuation of REZDIFFRA without any therapeutic intervention.
Monitor patients during treatment with REZDIFFRA for elevations in liver tests and for the development of liver-related adverse reactions. Monitor for symptoms and signs of hepatotoxicity (e.g., fatigue, nausea, vomiting, right upper quadrant pain or tenderness, jaundice, fever, rash, and/or eosinophilia [>5%]). If hepatotoxicity is suspected, discontinue REZDIFFRA and continue to monitor the patient. If laboratory values return to baseline, weigh the potential risks against the benefits of restarting REZDIFFRA. If laboratory values do not return to baseline, consider DI-ALH or autoimmune liver disease in the evaluation of elevations in liver tests.
In clinical trials, cholelithiasis, acute cholecystitis, and obstructive pancreatitis (gallstone) were observed more often in REZDIFFRA-treated patients than in placebo-treated patients. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated. …
Resmetirom side effects
The following clinically significant adverse reactions are described elsewhere in labeling:
Hepatotoxicity
Gallbladder-Related Adverse Reactions
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of REZDIFFRA was evaluated in two randomized, double-blind, placebo-controlled trials that enrolled a total of 2019 patients.
Trial 1
Trial 1 included patients who had noncirrhotic MASH with stages F2 and F3 fibrosis at eligibility (n=888) .
Adverse Reactions Leading to Discontinuations
The exposure-adjusted incidence rates (EAIRs) per 100 person-years (PY) for treatment discontinuation due to any adverse reaction were higher in the REZDIFFRA dosage arms: 4 per 100 PY, 5 per 100 PY, and 8 per 100 PY in placebo, REZDIFFRA 80 mg once daily, and REZDIFFRA 100 mg once daily arms, respectively. Diarrhea and nausea were the most common causes of treatment discontinuation.
Common Adverse Reactions
Table 1 displays EAIRs per 100 PY for the common adverse reactions that occurred in at least 5% of patients with F2 or F3 fibrosis treated in either drug arm with REZDIFFRA and were greater than that reported for placebo.
a Population includes adult patients with noncirrhotic MASH with liver fibrosis (stages F2 and F3 at eligibility). …
Drug interactions
Table 3 includes clinically significant drug interaction effects of strong or moderate CYP2C8 inhibitors on REZDIFFRA.
Clinical Impact | Resmetirom is a CYP2C8 substrate. Concomitant use with a strong or moderate CYP2C8 inhibitor can increase resmetirom Cmax and AUC , which may increase the risk of REZDIFFRA adverse reactions.
Intervention | Concomitant use of REZDIFFRA with strong CYP2C8 inhibitors (e.g., gemfibrozil) is not recommended. Reduce REZDIFFRA dosage if used concomitantly with a moderate CYP2C8 inhibitor (e.g., clopidogrel) .
Table 4 includes clinically significant drug interactions affecting other drugs.
Statins (Atorvastatin, Pravastatin, Rosuvastatin, or Simvastatin)
Clinical Impact | REZDIFFRA increased plasma concentrations of some statins (atorvastatin, pravastatin, rosuvastatin and simvastatin)
, which may increase the risk of adverse reactions related to these
drugs.
Intervention | Rosuvastatin and simvastatin: Limit daily statin dosage to 20 mg. Pravastatin and atorvastatin: Limit daily statin dosage to 40 mg.
CYP2C8 Substrates
Clinical Impact | Resmetirom is a weak CYP2C8 inhibitor. Resmetirom increases exposure of CYP2C8 substrates
, which may
increase the risk of adverse reactions related to these substrates. …
About this medicine
REZDIFFRA (resmetirom) tablets contain resmetirom, a thyroid hormone receptor-beta agonist. The chemical name for REZDIFFRA is 2-[3,5-Dichloro-4-((6-oxo-5-(propan-2-yl)-1,6-dihydropyridazin-3-yl)oxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile. The molecular formula is C17H12Cl2N6O4 and the molecular weight is 435.22. The chemical structure is:
Resmetirom has low aqueous solubility below pH 6 and higher solubility above pH 7 (0.44 mg/mL at pH 7.04).
REZDIFFRA tablets are supplied in 60 mg, 80 mg, and 100 mg strengths for oral administration. Each tablet contains the active ingredient, resmetirom, and the following USP/NF excipients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, mannitol, and microcrystalline cellulose. REZDIFFRA tablets are film-coated with an Opadry coating comprised of polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, red iron oxide (100 mg tablets), yellow iron oxide (80 mg and 100 mg tablets).
How it works: Resmetirom is a partial agonist of the thyroid hormone receptor-beta (THR-β). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID e67ea09f-a840-439c-86c8-f98585f978b2. Read the full official label on DailyMed.
Related medicines
Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin